


Application No. 09/090,492, filed June 3, 1998, which is, in turn, a continuation-in-part of International Application No. PCT/US97/22406, filed December 3, 1997, which, in turn, claims priority benefit of U.S. Provisional Application No. 60/033,159, filed December 13, 1996, the disclosures of all of which are incorporated herein by reference.

# IN THE CLAIMS




Please cancel claims 3-5, 7, 13, 15 to 21 and 42, without prejudice.

Please amend claims 1, 2, 8, 11, 12, 22, 23 and 25-29 as follows:


1. (Amended) A compound of formula I



wherein  $\text{Ar}^1$  is an optionally substituted moiety of formula



, or



→ elected ←

in which W is  $\text{NR}_{11}$ , wherein  $\text{R}_{11}$  is H, alkyl, aralkyl, heteroaralkyl or  $\text{R}_8(\text{O})\text{CCH}_2-$ , and A is CH;

Z is alkylene,  $-(\text{CH}_2)_r\text{C}(\text{O})\text{NR}''(\text{CH}_2)_s-$ ,  $-(\text{CH}_2)_s\text{R}''\text{NC}(\text{O})(\text{CH}_2)_r-$  or  $-(\text{CH}_2)_s\text{NR}''(\text{CH}_2)_r-$ ;

$R_1$  is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl,  $R'O(CH_2)_X-$ ,  $R'O_2C(CH_2)_X-$ ,

$R'C(O)(CH_2)_X-$ ,  $Y^1Y^2NC(O)(CH_2)_X-$  or  $Y^1Y^2N(CH_2)_X-$ ;

$R'$  and  $R''$  are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkenyl, substituted aralkenyl, heteroaralkenyl, substituted heteroaralkenyl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl;

$R_2$  is hydrogen, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, aralkenyl, substituted aralkenyl, heteroaralkenyl, substituted heteroaralkenyl,

$R_3R_4NC(O)(CH_2)_X-$ ,  $R_3S(O)_p-$  or  $R_3R_4NS(O)_p-$ ;

$R_3$  is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, aralkenyl, substituted aralkenyl, heteroaralkenyl or substituted heteroaralkenyl, or  $R_1$  and  $R_3$  taken together with the  $-N-S(O)_p-$  moiety or the  $-N-S(O)_p-NR_4-$  moiety through which  $R_1$  and  $R_3$  are linked form a 5 to 7 membered heterocyclyl or substituted heterocyclyl; and

$R_4$  is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl, or  $R_3$  and  $R_4$  taken together with the nitrogen to which  $R_3$  and  $R_4$  are attached form a 4 to 7 membered heterocyclyl or substituted heterocyclyl;

$X_1$  and  $X_{1a}$  are independently selected from H, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl, or  $X_1$  and  $X_{1a}$  taken together form oxo;


$X_2$  and  $X_{2a}$  taken together form oxo;

$X_3$  is H, hydroxy, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted

heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl, or  $X_3$  and one of  $X_1$  and  $X_{1a}$  taken together form a 4 to 7 membered cycloalkyl;

$X_4$  is H, alkyl, substituted alkyl, aralkyl or substituted aralkyl;

$X_5$ ,  $X_{5a}$  and  $X_{5b}$  are independently selected from H,  $R_5R_6N-$ , (hydroxy)HN-, (alkoxy)HN-, or (amino)HN-,  $R_7O-$ ,  $R_5R_6NCO-$ ,  $R_5R_6NSO_2-$ ,  $R_7CO-$ , halo, cyano, nitro and  $R_8(O)CCH_2-$ , and one of  $X_5$ ,  $X_{5a}$  and  $X_{5b}$  is a substituent that is alpha to a nitrogen of the ring of



that is distal to Z and is selected from the group consisting of H, hydroxy,  $H_2N-$ , (lower alkyl and substituted lower alkyl)HN-, (hydroxy)HN-, (alkoxy)HN- and (amino)HN-;

$Y^1$  and  $Y^2$  are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl, or  $Y^1$  and  $Y^2$  taken together with the N through which  $Y^1$  and  $Y^2$  are linked form a 4 to 7 membered heterocyclyl;

$R_5$  and  $R_6$  are independently H, lower alkyl or substituted lower alkyl, or one of  $R_5$  and  $R_6$  is H and the other of  $R_5$  and  $R_6$  is  $R_8(O)CCH_2-$  or lower acyl;

$R_7$  is H, lower alkyl, substituted lower alkyl, lower acyl or  $R_8(O)CCH_2-$  ;

$R_8$  is H, optionally substituted lower alkyl, alkoxy or hydroxy;

m is 1; p and r are independently 1 or 2; s is 0, 1 or 2; and x is 1, 2, 3, 4, or 5, or

a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof.

2. (Amended) The compound of claim 1, wherein:

*Sub*  
*B1*  
*A2*

Z is alkylenyl;

R<sub>1</sub> is hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, R'O(CH<sub>2</sub>)<sub>x</sub>-, R'O<sub>2</sub>C(CH<sub>2</sub>)<sub>x</sub>-, Y<sup>1</sup>Y<sup>2</sup>NC(O)(CH<sub>2</sub>)<sub>x</sub>-, or Y<sup>1</sup>Y<sup>2</sup>N(CH<sub>2</sub>)<sub>x</sub>-;

R' is hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl;

R<sub>2</sub> is R<sub>3</sub>S(O)<sub>p</sub>- or R<sub>3</sub>R<sub>4</sub>NS(O)<sub>p</sub>-;

R<sub>3</sub> is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, aralkenyl, substituted aralkenyl, heteroaralkenyl or substituted heteroaralkenyl, or R<sub>1</sub> and R<sub>3</sub> taken together with the -N-S(O)<sub>p</sub>- moiety or the -N-S(O)<sub>p</sub>-NR<sub>4</sub>- moiety through which R<sub>1</sub> and R<sub>3</sub> are linked form a 5 to 7 membered heterocyclyl or substituted heterocyclyl;

R<sub>4</sub> is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl, or R<sub>3</sub> and R<sub>4</sub> taken together with the nitrogen to which R<sub>3</sub> and R<sub>4</sub> are attached form a 4 to 7 membered heterocyclyl or substituted heterocyclyl; and

Y<sup>1</sup> and Y<sup>2</sup> are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaralkyl or optionally substituted heteroaralkyl, or Y<sup>1</sup> and Y<sup>2</sup> taken together with the N through which Y<sup>1</sup> and Y<sup>2</sup> are linked form a 4 to 7 membered heterocyclyl; or



a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof.


8. (Amended) The compound of claim 1 wherein R<sub>1</sub> is H, heteroaralkyl, substituted heteroaralkyl, aralkyl, substituted aralkyl, alkyl or substituted alkyl.

11. (Amended) The compound of claim 9 wherein R<sub>3</sub> is phenyl, substituted phenyl, naphthyl, substituted naphthyl, thienyl, substituted thienyl, benzothienyl, substituted benzothienyl, thienopyridyl, substituted thienopyridyl, quinoliny, substituted quinoliny, isoquinoliny or optionally substituted isoquinoliny.

12. (Amended) The compound of claim 1 wherein Z is methylenyl.

22. (Amended) The compound of claim 1, wherein Z is bonded to said moiety through the 5 membered ring.

23. (Amended) The compound of claim 1 wherein one of X<sub>5</sub>, X<sub>5a</sub> and X<sub>5b</sub> is a substituent that is on the  ring proximal to Z, at a position that is alpha to where Z is attached to  and is selected from the group consisting of H, hydroxy and amino.

25. (Amended) The compound of claim 1 wherein said one of X<sub>5</sub>, X<sub>5a</sub> and X<sub>5b</sub> that substitutes the ring of  distal to Z at the position alpha to a nitrogen thereof is H or (H, lower alkyl, substituted lower alkyl, hydroxy or amino)HN-.

26. (Amended) A compound according to claim 1 which is selected from 1-(4-Aminoquinazolin-7-ylmethyl)-3-(S)-[(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)amino]pyrrolidin-2-one;

2-(5-Chlorothiophen-2-yl)ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)pyrrolidin-3-(R)-yl]amide;

{[2-(5-Chlorothiophen-2-yl)ethenesulfonyl]-[2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)pyrrolidin-3-(R)-yl]amino}acetic acid isopropyl ester;


5'-Chloro-[2,2']bithiophenyl-5-sulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3-(S)-yl]-amide;


2-(5-Chloro-thiophen-2-yl)-ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3-(S)-yl]-amide; and


2-(5-Chloro-thiophen-2-yl)-ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3-(S)-yl]-amide.

27. (Amended) A compound according to claim 1 which is selected from 2-(5-Chloro-thiophen-2-yl)-ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3-(S)-yl]-amide and thieno[3,2-b]pyridine-2-sulfonic acid [2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-pyrrolidin-3-(S)-yl]-amide ditrifluoroacetate.


28. (Amended) A compound according to claim 1 wherein X<sub>1</sub>, X<sub>1a</sub>, X<sub>3</sub> and X<sub>4</sub> are H; and R<sub>2</sub> is a radical selected from the group consisting of













**THE UNIVERSITY OF CHICAGO**





$X_4$  are H;



Chemical structure of a pyrazole ring with a wavy line indicating a substituent at the 3-position.